http://www.fpnotebook.com/
AtovaquoneAka: Mepron, Malarone
- Indications
- Human Immunodeficiency Virus (HIV)
- Pneumocystis carinii Pneumonia prophylaxis
- Pneumocystis carinii Pneumonia treatment
- Patients unable to tolerate Bactrim
- Malaria Prophylaxis and Treatment (Malarone)
- Third line agent (Mefloquine preferred)
- Babesiosis
- Human Immunodeficiency Virus (HIV)
- Dosing: Pneumocystis carinii Pneumonia
- Prophylaxis: 1500 mg PO qd with food
- Treatment: 750 mg PO bid with food for 21 days
- Dosing: Malaria (Atovaquone/Proguanil or Malarone)
- Adults
- Prophylaxis: 1 tablet (250 mg/100 mg) PO qd
- Treatment: 4 tablets (1000 mg/400 mg) PO qd for 3 day
- Children
- Weight: 11-20 kg
- Prophylaxis: 1 tablet (62.5 mg /25 mg) PO qd
- Treatment: 1 tablet (250 mg/100 mg) PO qd
- Weight: 21-30 kg
- Prophylaxis: 1 tablet (125 mg /50 mg) PO qd
- Treatment: 2 tablet (250 mg/100 mg) PO qd
- Weight: 31-40 kg
- Prophylaxis: 1 tablet (187.5 mg /75 mg) PO qd
- Treatment: 3 tablet (250 mg/100 mg) PO qd
- Weight: >40 kg (Adult dose)
- Prophylaxis: 1 tablet (250 mg /100 mg) PO qd
- Treatment: 4 tablet (250 mg/100 mg) PO qd
- Weight: 11-20 kg
- Adults
- Precautions: Poor absorption
- Take with food (fatty meal) to ensure absorption
- Up to 10% of patients still may not absorb Mepron
- Efficacy: HIV
- Not as clinically active as Bactrim
- Pneumocystis Pneumonia treatment Failure rate: 17%
- Contrast with 6% for Bactrim
- Adverse effects
- Less dose-limiting adverse reactions than Bactrim
- Atovaquone: 7%
- Bactrim: 20%
- Rash
- Abdominal Pain
- Nausea or Vomiting
- Diarrhea
- Headache
- Mild Liver Function Test abnormalities
- Less dose-limiting adverse reactions than Bactrim
- Drug Interactions: Reduced plasma levels of Atovaquone
- Tetracycline
- Metoclopramide (Reglan)
- Rifampin
- References
Atovaquone (C0165603) | |
|---|---|
| Definition (CSP) | broad-spectrum antiparasitic drug found to be active against Pneumocystis carinii pneumonia in AIDS patients. |
| Definition (MSH) | A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols. |
| Definition (NCI) | A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D053626 |
| English | Atovaquone, Atovaquone - chemical, ATOVAQUONE PREPARATION |
| Spanish | atovacuona |
| Parent Concepts | Antifungal Agents (C0003308), Antiparasitic Agents (C0003404), Antiprotozoal Agents (C0003416), Naphthoquinones (C0027388), [AP109] ANTIPROTOZOALS, OTHER (C0973489), Drug allergen (C1320237), Duplicate concept (C1274013), Antiprotozoals (Non-antimalarials) (C1579412) |
| Sources | CSP, MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Mepron (C0378468) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D053626 |
| English | atovaquone GlaxoSmithKline brand, Glaxo Wellcome brand of atovaquone, GlaxoSmithKline brand of atovaquone, Mepron, Wellvone |
| Sources | CSP, MSH, NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
malarone (C0595490) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C109496 |
| English | malarone |
| Sources | MSH, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |